What is the regulatory status of Selank (Intranasal)?

Selank (Intranasal) regulatory status: Unapproved (Russia approved) in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does Selank (Intranasal)'s half-life affect dosing?

Selank (Intranasal) has a plasma half-life of CNS effect hours, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3 sprays daily for 2-4 week courses dosing at 300 mcg per spray per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

How long until I see results from Selank (Intranasal)?

Acute effects from Selank (Intranasal) appear within hours of dosing for receptor-level changes. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

How does Selank (Intranasal) interact with female hormonal cycling?

Cyclical hormone background influences how Selank (Intranasal) is distributed, metabolised, and felt. Even where the compound's pharmacology is not directly hormonal, response often varies across follicular and luteal phases. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

What route should I use for Selank (Intranasal)?

Selank (Intranasal) is delivered by intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Home/ Compounds/ Selank (Intranasal)

Selank (Intranasal)

Women's Health

Women's-health applications of Selank (Intranasal) require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Same Selank molecule; olfactory pathway bypasses BBB. Dosing at 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal with cycle-phase-aware tracking is the standard protocol for premenopausal users.

Female Physiology Applications

Libido (Female)MenopauseFertilityCognitive (Cycle/Menopause)Bone Density

Key Takeaways

Female-physiology lens: Selank (Intranasal) response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Same Selank molecule; olfactory pathway bypasses BBB.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Same Selank molecule; olfactory pathway bypasses BBB. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. Selank (Intranasal)'s contribution to each varies; the subsections below work through these in turn.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Selank (Intranasal) is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Fertility and reproductive considerations

Selank (Intranasal)'s effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Selank (Intranasal)'s effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Female Physiology Applications

Endometriosis Support

For endometriosis support in female users, Selank (Intranasal) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

PCOS Support

In the perimenopausal window, Selank (Intranasal) for pcos support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Skin Health

Skin Health is one of the dimensions on which women track Selank (Intranasal) response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Mood (Cycle-Related)

For mood (cycle-related) in female users, Selank (Intranasal) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray	4–6 weeks initial cycle
Women's Health focus	Intranasal	300 mcg per spray	2-3 sprays daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray	Ongoing with periodic pauses

Dose timing for Selank (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Selank (Intranasal) + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Selank (Intranasal)'s mechanism in female physiology protocols.
Selank (Intranasal) + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Selank (Intranasal)'s mechanism in female physiology protocols.
Selank (Intranasal) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Selank (Intranasal)'s mechanism in female physiology protocols.
Selank (Intranasal) + Epithalon: Identified by Khavinson in St. Pairs naturally with Selank (Intranasal)'s mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent. Mild nasal irritation possible.

Lens-specific safety considerations for female physiology use of Selank (Intranasal): Excellent. Mild nasal irritation possible. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank in GAD

PMID 21443549

Selank (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Selank (Intranasal)	Tuftsin-derived heptapeptide (intranasal)	CNS effect hours	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Can I use Selank (Intranasal) during pregnancy or while trying to conceive?

Most peptide therapeutics, including Selank (Intranasal), do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

How will Selank (Intranasal) interact with my cycle?

For pre-menopausal users, response to Selank (Intranasal) often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Is Selank (Intranasal) appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

What is Selank (Intranasal)?

Selank (Intranasal) (also known as Intranasal Selank) is a 7-residue tuftsin-derived heptapeptide (intranasal) with a molecular weight of 751 Da and a plasma half-life of CNS effect hours. Same Selank molecule; olfactory pathway bypasses BBB. The compound is studied primarily in the female physiology domain for the applications outlined above.

What is the standard dosing protocol for Selank (Intranasal)?

Conventional Selank (Intranasal) dosing is 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a Selank (Intranasal) Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Selank (Intranasal) and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Selank (Intranasal)

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised